Výsledky vyhledávání - "H C, Falkson"

Cyclophosphamide, doxorubicin and fluorouracil (CAF) plus the treatment of premenopausal women with metastatic breast cancer

Autor: H. C. Falkson, Geoffrey Falkson, Carla I. Falkson

Publikováno v: Annals of Oncology. 3:849-853

Summary A phase II study was undertaken to assess the effect of CAF plus depo-buserelin, as first-line treatment, in premenopausal women with breast cancer. Of 66 patients entered 60 are eligible and evaluable; their median age was 45, estrogen recep

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::dc52840c1bbf7131cc39cc800c346f23
https://doi.org/10.1093/oxfordjournals.annonc.a058109

Zobrazit plný text záznamu

Effect of chemotherapy with or without buserelin on serum hormone levels in premenopausal women with breast cancer

Autor: Geoffrey Falkson, H. C. Falkson, Carla I. Falkson

Publikováno v: European Journal of Cancer and Clinical Oncology. 27:1208-1211

Serial determinations of serum oestradiol (E2), follicle-stimulating hormone (FSH) and luteinising hormone (LH) were done to assess the effect of chemotherapy, with or without a gonadotropin-releasing hormone analogue, buserelin, on ovarian function

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1ee3b3b26797942d85fd1befa35b50a4
https://doi.org/10.1016/0277-5379(91)90082-o

Zobrazit plný text záznamu

Long-term survival of patients treated with combination chemotherapy for metastatic breast cancer

Autor: Robert S. Witte, Douglass C. Tormey, Patrick Carey, Geoffrey Falkson, H. C. Falkson

Publikováno v: European Journal of Cancer and Clinical Oncology. 27:973-977

Long-term survival of patients with metastatic breast cancer treated on two prospective stratified randomised trials has been analysed. Patients on study B122 received either cyclophosphamide, methotrexate and 5-fluorouracil (CMF) or cyclophosphamide

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bb82fc7a0f276397648b4b58901d556e
https://doi.org/10.1016/0277-5379(91)90261-b

Zobrazit plný text záznamu

Adjuvant trial of 12 cycles of CMFPT followed by observation or continuous tamoxifen versus four cycles of CMFPT in postmenopausal women with breast cancer: an Eastern Cooperative Oncology Group phase III study

Autor: W. H. Wolberg, K W Gillchrist, Jules E. Harris, Robert Gray, G Falkson, H. C. Falkson, Douglass C. Tormey

Publikováno v: Journal of Clinical Oncology. 8:599-607

A prospectively controlled randomized trial to compare the adjuvant efficacy of 12 cycles of cyclophosphamide, methotrexate, fluorouracil, prednisone, and tamoxifen (CMFPT) followed by observation or a total of 5 years of continuous tamoxifen versus

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::20e2008bff15d907bc3c3a8b1c682f21
https://doi.org/10.1200/jco.1990.8.4.599

Zobrazit plný text záznamu

Prognostic factors in metastatic malignant melanoma. An analysis of 236 patients treated on clinical research studies at the Department of Medical Oncology, University of Pretoria, South Africa from 1972-1992

Autor: C I, Falkson, H C, Falkson

Publikováno v: Oncology. 55(1)

Prognostic factors in 236 patients with metastatic malignant melanoma were analyzed. The patients were all entered on clinical research studies at a single institution. Univariate and multivariate analyses were performed on data which was prospective

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::a339d712bee5798fd7ddf41909176143
https://pubmed.ncbi.nlm.nih.gov/9428377

Zobrazit plný text záznamu

Postchemotherapy adjuvant tamoxifen therapy beyond five years in patients with lymph node-positive breast cancer. Eastern Cooperative Oncology Group

Autor: D C, Tormey, R, Gray, H C, Falkson

Publikováno v: Journal of the National Cancer Institute. 88(24)

Data from a pilot study published in 1984 suggested that tamoxifen administration (as adjuvant hormonal therapy) for more than 5 years after initial breast cancer surgery might have therapeutic benefit.A randomized trial was performed to assess the e

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::a4743127bd2a097019d951dd46c30fc1
https://pubmed.ncbi.nlm.nih.gov/8961967

Zobrazit plný text záznamu

A randomised study of CGS 16949A (fadrozole) versus tamoxifen in previously untreated postmenopausal patients with metastatic breast cancer

Autor: Carla I. Falkson, H. C. Falkson

Publikováno v: Annals of oncology : official journal of the European Society for Medical Oncology. 7(5)

Summary Background Fadrozole, a potent, highly specific inhibitor of aromatase activity, has only been used as second-line therapy in treatment of post-menopausal women with advanced breast cancer. A prospectively randomised study was therefore under

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7e1fa53e4dd245497fcb28a1df9b75a7
https://pubmed.ncbi.nlm.nih.gov/8839895

Zobrazit plný text záznamu

Follow-up results of an ECOG study of adjuvant therapy in post-menopausal women with breast cancer

Autor: H. C. Falkson, Robert Gray, W. H. Wolberg, G. Falkson

Publikováno v: Cancer Treatment An Update ISBN: 9782817807676

In 1982 the Eastern Cooperative Oncology Group started a prospectively controlled, randomized trial in postmenopausal women with operable node positive breast cancer. The aim of the study was to compare the adjuvant efficacy of 4 cycles versus 12 cyc

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::8dd0532c337517e347ecb962a96cf2da
https://doi.org/10.1007/978-2-8178-0765-2_30

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání